Senior Accounting Manager

The posting, as BillionToOne wrote it

A Rare Opportunity to Shape the Future of Genomics

Join a team of brilliant, passionate innovators determined to transform healthcare. At BillionToOne, we've built a category-defining, publicly traded company on Nasdaq where transparency fuels trust, collaboration drives breakthroughs, and every contribution moves the needle on our mission to make life-changing diagnostics accessible to all. We don't just aim for incremental improvements; we build products that are 10x better than anything that exists today.

Our scientists, engineers, sales executives, and visionaries are united by an unwavering commitment to changing the standard of care in prenatal and cancer diagnostics. This is where cutting-edge science meets human compassion, and every innovation you contribute helps remove the fear of the unknown from some of life's most critical medical moments.

If you're driven by purpose, energized by innovation, and ready to help shape the future of precision medicine at scale, this is where you belong.

The Senior Accounting Manager will oversee the accounting operations of a newly public company in its first full year of SOX 404(b) compliance, including managing the month-end close process, owning the integrity of the general ledger, and serving as a named control owner within our SOX framework. Reporting to the Director of Accounting, this role leads a team of GL and AP accountants, acts as a primary day-to-day contact for our external auditors, and is accountable for the monthly management reporting package including flux analysis and cost-per-test economics. The ideal candidate has experience in a fast-paced, post-IPO environment and brings the experience and knowledge to drive operational and process improvements.

Responsibilities

• Month-End Close: Manage the month-end and quarter-end close on a dependency-gated calendar in FloQast, including the journal entry control log, reconciliation sign-offs, and close checklist completion driving continuous compression of the close timeline while raising quality and audit-readiness.
• General Ledger Oversight: Own the accuracy and integrity of the general ledger in NetSuite, including review of recurring and non-standard journal entries, balance sheet reconciliations across the full account population, and root-cause resolution of posting and configuration issues.
• Internal Controls (SOX 404(b)): Serve as a named owner and reviewer for financial reporting, GL, and close-cycle controls. Maintain control narratives and supporting documentation, ensure IPE (information produced by the entity) meets completeness and accuracy standards, and remediate deficiencies with urgency. Coordinate submission of deliverables with key business partners.
• Audit & Compliance: Act as a day-to-day point of contact for our Big 4 external auditor and consulting advisors, managing PBC requests, walkthrough support, sample pulls, and interim and year-end fieldwork.
• Financial Reporting & Flux Analysis: Own the m

[…]
status, veteran status, or disability status.

For more information about how we protect your information, we encourage you to review our Privacy Policy .

BillionToOne is a next-generation molecular diagnostics company on a mission to make powerful, accurate diagnostic tests accessible to everyone. Our revolutionary QCT molecular counting technology enhances disease detection resolution by over a thousandfold using cell-free DNA,a breakthrough that has already transformed the lives of over half a million patients worldwide.

Our Impact

Unity Complete™ is the only non-invasive prenatal screen capable of assessing fetal risk for both common recessive conditions and aneuploidies from a single maternal blood sample.
Unity Confirm™ enables non-invasive confirmation for high-risk screening results through the capture of intact circulating fetal cells using BillionToOne’s Fetal Cell Capture™ Technology.
Our Northstar® liquid biopsy test uniquely combines treatment selection with real-time monitoring, giving oncologists unprecedented precision in cancer care.

Our Growth

From $0 to $400M+ annualized revenue run-rate in just 6 years. In 2025, we completed one of the most successful IPOs for a medical diagnostics company, building on nearly $400M in private funding,including our $130M Series D in 2024 and backed by world-class investors including Hummingbird, Adams Street Partners, Neuberger Berman, Baillie Gifford, and Premji Invest.

Our Recognition

Forbes named us one of America's Best Startup Employers for 2025 and we're Great Place to Work certified , with 100% of our people willing to go the extra mile, even as we've scaled to over 700 employees.

Our Future

Headquartered in Menlo Park with facilities in Union City, CA, and a new lab opening in Austin, TX in 2027, we're continuing to push the boundaries of what's possible in molecular diagnostics. We're just getting started.

Ready to help us change the world, one molecule at a time? Learn more at billiontoone.com